The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | METTL3 upregulation leads to aggressive CLL
In this video, Lili Wang, MD, PhD, City of Hope, Duarte, CA, discusses METTL3 and its contribution to aggressive chronic lymphocytic leukemia (CLL). It has been determined that METTL3 upregulation can promote post-transcriptional upregulation of splicing factors which in turn leads to splicing dysregulation, a contributor to the aggressive nature of CLL. According to Dr Wang, METTL3 shows potential as a drug target in those patients in which upregulation is seen and a Phase I clinical trial of a METTL3 inhibitor is currently underway. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
